BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease

Study 701-301 is a single-arm, open-label, switchover study in patients with late-onset Pompe disease who have been receiving treatment with recombinant human acid alpha-glucosidase (rhGAA) for 48 weeks or longer. Ambulatory patients who have mild to moderate respiratory impairment will switch directly to receive BMN 701 20 mg/kg by IV infusion every other week. All participants will receive active drug. No dose of existing therapy will be missed - experimental drug is started immediately.

Study Overview

• Status: Terminated
• Conditions: Late-onset Pompe Disease
• Intervention / Treatment: Drug: BMN 701

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Edegem, Belgium
    • Antwerp University Hospital (UZA)
• France
  • Garches, France, 92380
    • Hôpital Raymond Poincaré
  • Marseille, France, 13005
    • CHU de la Timone
• Germany
  • Mainz, Germany
    • Villa Metabolica, ZKJM MC University Mainz
  • München, Germany
    • Klinikum der Universität München
  • Münster, Germany, 48149
    • Universitätsklinikum Münster
• Italy
  • Milano, Italy, 20133
    • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
  • ME
    • Messina, ME, Italy, 98125
      • Azienda Ospedaliera Universitaria Policlinico "G. Martino" - Messina
• Netherlands
  • Rotterdam, Netherlands, 3015 GJ
    • Erasmus MC University Medical Center
• Portugal
  • Porto, Portugal, 4200-319
    • Centro Hospitalar de Sao Joao, EPE
• United Kingdom
  • Birmingham, United Kingdom
    • University Hospital Birmingham
  • London, United Kingdom, NW3 2QG
    • Royal Free Hospital
  • London, United Kingdom
    • National Hospital For Neurology and Neurosurgery
  • Salford, United Kingdom, M5 5AP
    • Salford Royal NHS Foundation Trust
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85028
      • Neuromuscular Research Centre
  • California
    • Orange, California, United States, 92868
      • University of California, Irvine
  • Florida
    • Gainesville, Florida, United States, 32610
      • University of Florida
  • Kansas
    • Kansas City, Kansas, United States, 66160
      • University Of Kansas Medical Center
  • Missouri
    • Saint Louis, Missouri, United States, 36110
      • Washington University
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke University Medical Center
  • Ohio
    • Columbus, Ohio, United States, 43210
      • The Ohio State University - Wexner Medical Center
  • Utah
    • Salt Lake City, Utah, United States, 84132
      • University of Utah

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Willing and able to provide written informed consent, after the nature of the study has been explained, and prior to any study-related procedures.
• Diagnosed with late-onset Pompe disease based on 2 currently or previously documented GAA gene mutations, and endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed by dried blood spot or whole blood assay.

• Has received prior treatment with commercial rhGAA as defined by ALL of the following:

  1. has received treatment with commercial rhGAA for ≥ 48 weeks (but no more than 20% of the study population can have received treatment for ≥ 6 years).
  2. has received > 80% of all scheduled treatments in the prior 48 weeks and ≥ 4 out of the prior 6 scheduled treatments.
  3. has received and completed the last two infusions without a drug-related adverse event resulting in dose interruption.
  4. has received last treatment of commercial rhGAA ≥ 10 and ≤ 31 days prior to anticipated initiation of treatment with BMN 701.
• ≥ 18 years of age at the time of enrollment in the study.
• Sexually active subjects must be willing to use two known effective methods of contraception while participating in the study and for at least 4 months following the last dose of BMN 701.
• Females of childbearing potential must have a negative pregnancy test at Screening and Baseline visits and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
• Has ≥ 30% predicted upright FVC and < 80% predicted upright FVC.
• Has ≤60% predicted MIP.
• Is able to ambulate ≥75 meters and ≤500 meters on the 6MWT conducted during the Screening visit (use of assistive devices such as walker, cane, or crutches, is permitted with consistent use throughout the study).
• Is willing and able to comply with all study procedures.

Exclusion Criteria:

• Use of any investigational product or investigational medical device within 4 weeks prior to Screening, or requirement for any investigational agent other than BMN 701 prior to completion of at least the first 24 weeks of all scheduled study assessments.
• Received any investigational medication for Pompe disease within the prior 12 months.
• Has a diagnosis of diabetes and/or is currently being treated with or anticipated to require treatment with hypoglycemic agents during the course of the study.
• Has been treated with any immunosuppressive medication other than glucocorticosteroids within the prior 12 months.
• Requires noninvasive ventilatory support while awake and in the upright position.
• Has previously been enrolled to this study.
• Breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
• Concurrent disease, medical condition, or extenuating circumstance that, in the opinion of the Investigator, might compromise subject safety, study treatment compliance and completion of the study, or the integrity of the data collected for the study.
• Has known hypersensitivity to BMN 701 or its excipients.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: BMN 701 20 mg/kg; BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)	Drug: BMN 701; BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Predicted Maximum Inspiratory Pressure (MIP)	Pulmonary function test: Percent Predicted Maximum Inspiratory Pressure	Baseline, Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Predicted Maximum Expiratory Pressure (MEP)	Pulmonary function test: Percent Predicted Maximum Expiratory Pressure	Baseline, Week 24
6 Minute Walk Test (Meters)	Distance walked within 6 minutes	Baseline, Week 24
Percent Predicted Upright Forced Vital Capacity (FVC)	Pulmonary function test: Percent Predicted Upright Forced Vital Capacity	Baseline, Week 24
Number of Participants With Non-Serious AEs	Number of participants with non-serious Adverse Events. Data is taken at final time point of Week 24, compared to baseline. For full AE data, please see AE section.	Baseline through Week 24 +4 weeks follow-up

Collaborators and Investigators

• Sponsor: BioMarin Pharmaceutical
• Investigators: Study Director: Study Monitor, BioMarin Pharmaceutical

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 1, 2014
• Primary Completion (ACTUAL): September 12, 2016
• Study Completion (ACTUAL): September 12, 2016

Study Registration Dates

• First Submitted: August 13, 2013
• First Submitted That Met QC Criteria: August 15, 2013
• First Posted (ESTIMATE): August 19, 2013

Study Record Updates

• Last Update Posted (ACTUAL): June 14, 2018
• Last Update Submitted That Met QC Criteria: June 12, 2018
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Lysosomal Storage Diseases, Nervous System; Glycogen Storage Disease; Glycogen Storage Disease Type II
• Other Study ID Numbers: 701-301; 2013-001768-48 (EUDRACT_NUMBER)